Skip to main content
. 2021 Oct 19;63(10):1323–1331. doi: 10.1177/02841851211041832

Table 2.

Accumulative tumor response, for the entire study period, using mRECIST in 73 patients with HCC who had TACE.

graphic file with name 10.1177_02841851211041832-img1.jpg

Values are given as n (%) unless otherwise indicated.

DC, disease control; HCC, hepatocellular carcinoma; mRECIST, modified Response Evaluation Criteria in Solid Tumors; OR, objective response; TACE, transarterial chemoembolization.